Lauren Tyra is the Chief Executive Officer of Gregor Diagnostics, leading the team through our quest to redefine prostate cancer care. She joined Gregor as an investor in 2018 and as CEO in 2024. Prior to Gregor, Lauren was the Chief Scientific Officer for a Texas-based, healthcare-focused venture capital firm, GPG Ventures. Lauren has BS in Biology and BA in German from the University of North Texas and a PhD from UT Southwestern in Neuroscience, where she was a National Science Foundation GRFP Fellow. In her free time, she reads, hangs out with her husband and high school sweetheart, and shuttles her 2 children around to numerous activities.

Duncan is the Chief Scientific Officer leading the R&D team at Gregor, which is responsible for all biomarker development, process development and optimization, and data sciences. Duncan joined Gregor in early 2022. Prior to that he was VP, Head of Early Detection for Lung Cancer at Johnson & Johnson, VP of Diagnostics at Curis, VP of Discovery R&D at Veracyte, and started his career in clinical research at Exact Sciences, as VP of Technology Development. Duncan has held other leadership roles in biotechnology development in his career and thrives on tackling intricate scientific problems, as well as building effective teams. Duncan received a PhD from Massachusetts Institute of Technology and a BA from Colby College. In his free time, he enjoys traveling, spending time with family, and staying active biking in the summer and skiing in the winter.

Tobias Zutz is the Chief Technology Officer and Founder of Gregor Diagnostics. After serving for 5 years as its founding CEO, he transitioned to Chief Technology Officer in 2021 to focus more directly on the technology for Gregor's testing. Prior to founding Gregor, he had a decade of R&D experience in assay development and molecular diagnostics. Most recently he was a member of the R&D team at Exact Sciences that developed Cologuard™, a novel screening assay for colon cancer. Before joining Exact, Mr. Zutz was with two small Madison-area biotech companies. He completed a BS in Biochemistry and Genetics and an MS in Biotechnology both from the University of Wisconsin. In his free time, he enjoys playing tennis, cooking, and rooting for all the Wisconsin based sports teams.

Mike Bress is the Chief Financial Officer, primarily working on Accounting, Finance, HR, IT, and Facilities. He has been with Gregor Diagnostics since 2021 and has built and led multiple Operations organizations, from small start-ups to multi-billion-dollar asset managers. Mike has an undergraduate degree in Economics from the University of Pennsylvania and an MBA with a focus on finance and strategy from Georgetown University. In his free time, he runs a large animal sanctuary and rescue in Colorado, and, when and where possible, travels to exotic locales with his kids and grandkids.

Michael Brawer Is the Chief Medical Officer of Gregor diagnostics overseeing all Medical Issues. He has been with Gregor since 2023. Prior to this he served similar position in several Prostate Therapeutic and Diagnostic companies including Threshold Therapeutics GTX, Myriad Genetics MDX Health and Nanospectra Biosciences. Michael received his M.D. from UCLA and trained in General Surgery and Urology at Stanford University. Prior to joining industry, he was Professor of Urology and Adjunct Professor of Pathology at the University of Washington and the Director of the Northwest Prostate Institute. In his spare time, he enjoys playing with his grandson, woodworking, skiing, and gardening. He is married with 3 adult children.